CareDx IncNASDAQ:CDNA
- LAST PRICE23.9250
- TODAY'S CHANGE (%)-0.1850 (-0.7673%)
- Bid / Lots23.7700/ 8
- Ask / Lots24.0800/ 8
- Open / Previous Close24.1500 / 24.1100
- Day Range
- 52 Week Range
- Volume13,967
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CDNA |
|---|---|---|
| 09:32 ET | 5439 | 23.94 |
| 09:33 ET | 2535 | 23.75 |
Nov 12, 2024
CareDx to Participate in Upcoming Investor Conferences, from 7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
DJ CareDx Is Maintained at Buy by BTIG, from 1:33PM ET on Tuesday Nov 05, 2024 by Dow Jones
1:33PM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones*DJ CareDx 3Q Loss/Shr 14c >CDNA, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CareDx Inc | 1.2B | -8.9x | --- |
Maravai LifeSciences Holdings Inc | 1.3B | -3.1x | --- |
MiMedx Group Inc | 1.4B | 18.3x | --- |
BioCryst Pharmaceuticals Inc | 1.6B | -12.0x | --- |
Aurinia Pharmaceuticals Inc | 1.3B | -55.2x | --- |
Dynavax Technologies Corp | 1.6B | 101.7x | --- |
Company Information
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Contact Information
- Headquarters
- 8000 Marina Blvd, 4Th FloorBRISBANE, CA, United States 94005
- Phone
- 415-287-2300
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Goldberg
- President, Chief Executive Officer, Director
- John Hanna
- Chief Financial Officer
- Abhishek Jain
- Chief Operating Officer
- Keith Kennedy
- General Counsel, Secretary
- Jeffrey Novack
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
|---|---|
Revenue (TTM) | $312.8M |
Shares Outstanding | 53.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-2.70 |
Book Value | $5.07 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | 4.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -50.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
